An exploratory study to investigate the immunomodulatory activity of BMS-936558 in patients with metastatic clear-cell renal cell carcinoma. Background: Standard treatments for metastatic renal cell ...
Bristol Myers Squibb is sharing its phase 2 results at the European Respiratory Society 2023 international congress this week. (Bristol Myers Squibb) After scoring in a more common form of pulmonary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results